MarginsXMarginsX
Home › Markets › Health Care › ORGO

Organogenesis Holdings Inc. (ORGO)

ORGO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.8031
-0.86% on the day
Market cap
$104.2M
Micro cap
Revenue · 2025
$564.2M
+17.0% on 2024
Net income · 2025
$37.0M
6.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1661181/000119312526076730/0001193125-26-076730-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerORGO on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2016
SEC CIK0001661181
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$564.2M
Net income$37.0M
Operating income$44.7M
Net margin6.6%
Operating margin7.9%
Revenue growth+17.0%
Cash$93.7M
Total assets$598.7M
P/E (computed)2.8×
P/S (computed)0.2×

Warning signs

Cash runway
Cash-flow positive
$21.3M cash at September 30, 2026
Share count, 1 year
+2.3%
2025-10-30 to 2026-10-30 · -1.7% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$2.6M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$21.3M cash; operating cash flow $2.6M a quarter.Report 2026-09-30
Shares outstanding129,801,720 (2026-10-30); 126,912,142 a year earlier; 132,041,164 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-08-06
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorRSM US LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-10
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $40K, sold $2.6M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$45.5M-$29.6M-$18.6M$21.3MNo debt tags$352.0M10-Q 2026-11-05
Q2 2026
2026-06-30
$43.8M-$96.3M-$31.7M$46.1MNo debt tags$457.5M10-Q 2026-08-06
Q1 2026
2026-03-31
$37.2M-$53.2M$21.1M$91.4MNo debt tags$514.7M10-Q 2026-05-07
Q4 2025
2025-12-31
$225.6M$43.7M$39.4M$93.7MNo debt tags$564.2M10-K 2026-02-26
Q3 2025
2025-09-30
$150.9M$21.6M$3.1M$63.7MNo debt tags$465.2M10-Q 2026-11-05
Q2 2025
2025-06-30
$101.0M-$9.4M-$32.9M$73.1MNo debt tags$429.5M10-Q 2026-08-06
Q1 2025
2025-03-31
$86.7M-$18.8M-$19.9M$110.0MNo debt tags$458.8M10-Q 2026-05-07
Q4 2024
2024-12-31
$126.7M$7.7M$10.9M$135.6MNo debt tags$482.0M10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-08-06
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEF 14A2026-04-30

Source: SEC EDGAR submissions feed, 673 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-0.4%
1 month-33.1%
3 months-54.0%
Year to date-84.4%
1 year-87.0%
From 52-week high-86.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
DERMJourney Medical Corporation$3.70-14.55%$104.5M
CLLSCellectis S.A.$1.04-11.86%$104.5M
UNCYUnicycive Therapeutics Inc.$3.70+4.23%$103.1M
ADAGAdagene Inc.$1.60-6.43%$105.7M
CUECue Biopharma Inc.$14.10-12.53%$102.4M
OGIOrganigram Global Inc. Common Shares$0.7240-12.62%$102.2M
BGMBGM Group Ltd.$8.01+1.71%$107.0M
FHTXFoghorn Therapeutics Inc.$1.79-13.53%$107.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier